This invention relates to certain chirally-correct mitoprotectant phosphorylated heterocyclic agents [formula (I)], which are useful for the treatment of dermatological disorders that include challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn； mitochondrial dysfunction； age spots； acne, loss of cellular antioxidants； skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV； dry skin； xerosis； ichthyosis； dandruff； brownish spots； keratoses； melasma； lentigines； liver spots； skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes； oily skin； warts； eczema； pruritic skin； psoriasis； inflammatory dermatoses； topical inflammation； disturbed keratinization； scalp dryness； skin depigmentation, and combinations thereof；
